These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19380285)

  • 1. Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
    Rosso R; Bernardini C; Bruzzone B; Secondo G; Icardi G; Viscoli C; Di Biagio A
    Eur J Med Res; 2009 Mar; 14(3):136-8. PubMed ID: 19380285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.
    Pinnetti C; Tamburrini E; Ragazzoni E; De Luca A; Navarra P
    Antivir Ther; 2010; 15(1):127-9. PubMed ID: 20167999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
    Arazo Garcés P; Omiste Sanvicente T
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
    Fagard C; Colin C; Charpentier C; Rami A; Jacomet C; Yeni P; Vittecoq D; Katlama C; Molina JM; Descamps D; Chêne G; Yazdanpanah Y;
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):489-93. PubMed ID: 22293546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
    Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Fletcher CV; Acosta EP;
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):294-296. PubMed ID: 27103489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
    Viganò A; Meroni L; Marchetti G; Vanzulli A; Giacomet V; Fasan S; Pradella A; Cerini C; Zuccotti GV
    Antivir Ther; 2008; 13(6):839-43. PubMed ID: 18839785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
    Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
    HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.
    Trottier B; Di Perri G; Madruga JV; Peeters M; Vingerhoets J; Picchio G; Woodfall BJ
    HIV Clin Trials; 2010; 11(4):175-85. PubMed ID: 20974573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
    Audelin AM; Lebech AM; Petersen AB; Jørgensen LB
    J Med Virol; 2008 Aug; 80(8):1319-21. PubMed ID: 18551616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.